Document:

Exhibit

Exhibit 10.2
7/30/2014
Mollie SPILMAN

Re:  Employment Offer Letter

Dear Mollie

On behalf of Criteo Corp., ("Criteo" or the "Company"), I am pleased to offer you the position of Chief Revenue Officer. The terms of your position with the Company, should you accept this offer, will be as set forth below:

Position and Salary. When you join the Company, your position will be Chief Revenue Officer and you will report to Chief Operating Officer Eric Eichmann.  You will generally work out of the Company's offices in New York, NY, but will be expected to travel, as required. As a Company employee, you will (i) carry out your duties, as directed by the Company, in a diligent, competent, faithful and professional manner; (ii) work with other employees of the Company in a competent and professional manner; and (iii) generally promote the interests of the Company. Your starting annual, base salary will be $ 450,000 (your "Salary") less applicable taxes, deductions and withholding. Your Salary will be payable in accordance with the Company's standard payroll practices and subject to annual review. The Company's business is fast-growing and changes quickly. As such, the Company may change your title and duties from time to time to suit its business needs, or change your Salary as it deems appropriate. In addition, the Company may transfer you to another location within the United States.

Bonus. You will also be eligible for a standard discretionary corporate bonus of $ 450,000. ("Target Bonus"), pro-rated based on the period of time you are employed at Criteo during the relevant year, less applicable taxes, deductions and withholdings. Target incentives do not constitute a promise of payment. Your actual bonus payout will depend on the Company's financial performance and management's assessment of your group or individual performance. Your bonus is capped at a maximum of 200% of the Target Bonus. The Board of Directors will determine in its sole discretion at the appropriate times whether the Company has achieved its targeted financial performance. Your bonus will be paid on a annual basis upon calculation of your actual achievement, as determined by the Company in its sole discretion. At any time, the Company may change, at its sole discretion, the way this bonus is structured, calculated and paid. In that case, the Company will ensure that you remain eligible for your Target Bonus in the case you achieve 100% of the targets given to you. The Board of Directors will review your Target Bonus periodically, and in its sole discretion, consider any increases/adjustments (including as to structure) it deems appropriate at that time. In order to be eligible for any bonus, you must be an active employee at, and not have given or received notice of termination of your employment prior to, the time of the payment of such bonus. Please note that payment of a bonus in any year or years does not in any way guarantee payment of a bonus in any other year or years.

In addition a sign on bonus will be granted in the amount of $100,000. This will need to be returned to the Company by the employee if he leaves prior to working one year with the Company.

Equity. As part of the Criteo team, we strongly believe that ownership of the Company is an important factor to our success.  Therefore, as part of your compensation, management will recommend to the Board of Directors, and subject  to the Board of Directors' prior approval, that  you be granted an option (the "Option") to purchase 200 000 ordinary shares (the "Shares") of Criteo S.A., the Company's parent company (the "Parent").  The exercise price per share for the Option will be the fair market value of the Parent's ordinary shares on the date of the grant, as determined by the Board of Directors. Your Option will be subject to the terms and conditions of the Criteo 2014 Stock Option Plan and the stock option agreement between you and the Parent. Your Option will vest and become exercisable over a four-year period starting from the date the Option is granted according to the following schedule: - up to one fourth (1/4) of the options as from each anniversary of the date of grant, and at the latest within ten (10) years as from the date of grant. Vesting of the Shares will, of course, depend on your continued employment with the Company.

Medical and Other Benefits. A significant part of your total compensation at Criteo is derived from the benefits that Criteo provides. As a Company employee, you will be eligible to participate in the Company's health insurance benefits (medical, dental and vision), life insurance, short term and long term disability and flexible spending plan that are available to full-time Company employees from time to time, subject to the terms and conditions of the applicable plan. Of course, Criteo may change or terminate such benefit plans or programs at any time in its sole discretion and subject to the eligibility requirements and rules of each such plan or program. You will be eligible to accrue up to ten (10) days of paid time off in your first full year of employment(pro-rated for your year of hire), fifteen (15) days in your second full year of employment, and twenty (20) days beginning in your fourth full year of employment with the Company. You can accrue up to 1.5 times your applicable accrual rate (the "Accrual Cap"). Once you reach the Accrual Cap, you will cease accruing paid time off until you use days and take your available balance below the Accrual Cap.

Protective Covenants Agreement. By signing this letter agreement, and as a condition to your employment with the Company, you agree to sign the Company's standard form of Protective Covenants Agreement.

No Conflicts. You represent and warrant to the Company that you are not bound by the terms of a non-competition or any other agreement with a former employer or other third party, or any other order, judgment or decree of any kind, which would preclude you from being employed by the Company or which would preclude you from effectively performing your duties for the Company. You further warrant that you have the right to make all disclosures that you have made or will make to the Company during the course of your employment by the Company. You agree that you shall not disclose to the Company, or otherwise use in connection with the services you render on behalf of the Company, any confidential or other proprietary information belonging to a former employer or other third party. You represent and warrant that you have returned to all prior employers any and all of their confidential or proprietary information or other property.

At-Will Employment. Please understand that this letter does not constitute a contract of employment for any specific period of  time, but will create an employment "at-will", meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company's human resources policies and procedures, may change from time to time, the "at will" nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company.

Notice of Termination. Notwithstanding the forgoing, in the event you terminate your employment with the Company for any reason, you agree to provide 14 days prior written notice of such termination to the Company. The Company shall have the right at any time during such notice period to (i) reduce or change your offices, duties and responsibilities, (ii) relieve you of your offices, duties and responsibilities and place you on a paid leave-of­absence, and/or (iii) waive or reduce such notice period with no further obligations to you, including but not limited to, making any payments to you in lieu of notice.

Outside Activities During Employment.

		
	(a)
	During your employment with the Company, you will devote all of your business time, best efforts and business judgment, skill and knowledge to the advancement of the Company's interests and to the discharge of your duties and responsibilities under this Agreement. You shall abide by all legal, professional, ethical and Company requirements, rules, regulations, policies and practices applicable to your work. The Company expects you to abide by all such restrictions or obligations and to avoid any act that could pose a conflict as a result of confidential, proprietary or trade secret information obtained by you prior to your employment by the Company. By agreeing to become employed by the Company, you represent that none of these restrictions or obligations is inconsistent with your serving as an employee of the Company.

		
	(b)
	During the term of your employment with the Company, you will not, without the Company's written consent, (1) form or attempt to form a business in competition with the Company; (2) render or perform services of a business, professional or commercial nature other than to  or for the Company, either alone or as an employee, consultant, director, officer or partner of another business entity, whether or  not for compensation, and whether  or not such activity, occupation or endeavor is similar to, competitive with or adverse to the business or welfare of the Company; or (3) invest in or become a shareholder of or consultant to another corporation or other entity, provided that your investment solely as a shareholder in another corporation shall not be prohibited hereby so long as such investment is not in excess of 1% of any class of shares that are traded on a national securities exchange.

Entire Agreement. This letter and the agreements referred to in this letter contain all of the terms of your employment with the Company and supersede any prior understandings or agreements, whether oral or written, between you and the Company. You acknowledge that you have not relied upon any representations (oral or otherwise) other than those explicitly stated in this letter and the agreements referred to in this letter.

Duties: without prejudice to the previous section, you will at all times comply with any codes, policies, procedures and rules of the Company. By signing this offer, you acknowledge that you have received a copy of Criteo's Code of Business Conduct and Ethics, you will comply with all its provision and you will, within 3 weeks following your start date carry out the Ethic's online training.

Amendment and Governing Law. This letter agreement may not be amended or modified except by an express written agreement signed by you and a duly authorized officer of the

Company. The terms of this letter agreement and the resolution of any disputes will be governed by the laws of the State of New York.

Eligibility to Work in the United States. This offer of employment is contingent upon the completion of reference checks satisfactory to the Company. Also, as required by law, your employment with the Company is contingent upon your providing legal proof of your identity and eligibility for employment to work in the United States.

Arbitration. By signing this letter agreement, and as a condition to your employment with the Company, you agree to sign the enclosed Arbitration Agreement.

Background Check. Please understand that this offer is contingent upon a background check (which shall be authorized by you). The Company will review the results of the background check and may, at its sole discretion, withdraw this offer of employment or terminate your employment upon such review.

Start Date. For purposes of this letter, your first day of work at Criteo is expected to be August 25th 2014 and will be considered your "Employment Date".

We are all delighted to extend you this offer and look forward to working with you. To indicate your acceptance of the Company's offer, please sign and date this letter and return before the offer expiration date of August 6th 2014.

	
			
	 
	Regards,

	 
	 

	 
	CRITEO CORP

	 
	 

	 
	 

	Effective Date: 8/6/14
	By:
	/s/ Dipti Salopek

	 
	 
	 

I have read and accept this employment offer:

	
				
	Candidate Name:
	/s/ Mollie Spilman
	Date:
	8/6/14

	 
	Mollie SPILMANEX-10.1

 Exhibit 10.1 
  

 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 February 13,
2017 
 Vifor (International) Ltd. 
 Rechenstrasse 37 

CH-9014 St. Gallen 
 Switzerland 

Re:     Grant of Rights to CCX168 in Expanded Territory 

Ladies and Gentlemen: 
 As you know, Vifor Fresenius Medical
Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated May 9, 2016 (the “VFMCRP Agreement”), pursuant
to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX168 in certain countries. Capitalized terms used but not otherwise defined in this letter agreement (this
“Letter”) will have the meanings provided in the VFMCRP Agreement. The VFMCRP Agreement was originally entered into between Vifor (International) Ltd. (“Vifor”) and ChemoCentryx and was subsequently assigned by
Vifor to VFMCRP, so that references in the VFMCRP Agreement to VIT now refer to VFMCRP. 
 ChemoCentryx now desires to grant to Vifor rights to CCX168 in
certain other countries that are consistent with the rights granted to VFMCRP in the VFMCRP Agreement, with the understanding that Vifor intends to assign such rights to VFMCRP prior to June 30, 2018. 

ChemoCentryx and Vifor, intending to be legally bound, hereby agree as follows: 

1. “Vifor Territory” means (i) all countries of the world excluding the U.S., China, Europe, Central America, South America,
Mexico, Canada, South Korea, and Africa and (ii) China, if China is added to the Vifor Territory pursuant to Section 1(a) below.  
 650
210.2900 Voice 
 650 210.2910 Fax 
 850 Maude Avenue 

Mountain View, CA 94043, USA
                                         
                                       Medicines
In Motion 

  

					
		 	1.	  	Confidential

 (a) ChemoCentryx shall notify Vifor within thirty (30) days after entering into a
written agreement with a Third Party for development of the Product for Regulatory Approval in China (a “China Agreement”). If ChemoCentryx has not entered into a China Agreement by [***], then Vifor may elect to expand the Vifor
Territory to include China by (i) delivering written notice of such expansion to ChemoCentryx and (ii) paying ChemoCentryx a one-time, non-refundable, non-creditable payment of [***] United States dollars (US$[***]), in each case
(i) and (ii) within thirty (30) days after [***]. Upon ChemoCentryx’s receipt of such notice and payment during such thirty (30)-day period, the Vifor Territory will automatically be expanded to include China. If ChemoCentryx
does not receive such notice and payment during such thirty (30)-day period, the Vifor Territory shall continue to exclude China. 

(b) “China” means the People’s Republic of China, the Hong Kong Special Administrative Region of the
People’s Republic of China and the Macao Special Administrative Region of the People’s Republic of China. 
 (c)
“China Agreement Revenue” means all amounts received by ChemoCentryx from a Third Party under a China Agreement, but specifically excluding: (a) amounts received in consideration of the issuance of equity or debt securities
of ChemoCentryx or its Affiliate; (b) payments for research, development, or commercialization activities undertaken by ChemoCentryx or its Affiliate; (c) reimbursements for amounts paid or costs incurred by or on behalf of ChemoCentryx or
its Affiliate, including patent prosecution, maintenance, enforcement or defense expenses; (d) amounts received as an extension of credit or loan or as a distribution of a patent enforcement award; or (e) payments for the supply of goods
and/or services. Notwithstanding the foregoing, if an upfront payment under a China Agreement includes amounts received in consideration of the issuance of equity or debt securities of ChemoCentryx or its Affiliate, [***], will be included in China
Agreement Revenue. [***]. In the event that ChemoCentryx grants rights to the Product along with a license to any proprietary technology or intellectual property related to products other than the Product, ChemoCentryx shall reasonably and in good
faith allocate the amounts received among all technology licensed or sublicensed, and China Agreement Revenue shall include only the portion allocated to the Product. For clarity, China Agreement Revenue excludes amounts received by ChemoCentryx
from a Third Party in connection with a sale of substantially all of the business or assets to which this Agreement relates. 

(d) Within sixty (60) days after the end of each Calendar Quarter in which ChemoCentryx receives China Agreement Revenue,
ChemoCentryx shall pay to Vifor an amount equal to [***] ([***]%) of all China Agreement Revenue received by ChemoCentryx during such Calendar Quarter. 

2. Subject to the terms and conditions of this Letter and the agreement referenced in Section 8(a) if and when entered into, as applicable,
ChemoCentryx hereby grants to Vifor an exclusive (even as to ChemoCentryx), royalty bearing license, with the right to grant sublicenses as provided under the terms of Section 2.2 of the VFMCRP Agreement (as applied to Vifor in place of VFMCRP,
and with Japan and China (if included in the Vifor Territory pursuant to 
  

 

	***	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  

					
		 	2.	  	Confidential

 
Section 1 above) being deemed Major Market Countries), under the ChemoCentryx Know-How and ChemoCentryx Patents (as applied to the Vifor Territory in place of the VIT Territory as referenced
in such defined terms in the VFMCRP Agreement) (a) to seek Regulatory Approval and Pricing and Reimbursement Approval for and Commercialize the Product in the Field in the Vifor Territory and (b) to conduct those Development activities in
the Field in the Vifor Territory allocated to Vifor in the Development Plan. 
 3. Notwithstanding Section 2 above, if Vifor intends to grant a
sublicense under the foregoing license, Vifor shall notify ChemoCentryx in writing. Any such sublicense shall be subject to and consistent with all terms of the VFMCRP Agreement, as if the sublicense were granted by VFMCRP under the VFMCRP Agreement
as amended by the amendment attached hereto as Exhibit A. No such sublicense may be granted unless and until Vifor and ChemoCentryx enter into an agreement governing at least the following: 

(a) Development of the Product for the sublicensed country(ies), which would be considered Additional Studies and subject to the
approval of the JSC (with decision-making authority as provided in the VFMCRP Agreement, as applied to the Vifor Territory in place of the VFMCRP Territory), unless agreed otherwise by ChemoCentryx and Vifor in writing; 

 

	 	(b)	Economic terms identical to the VFMCRP Agreement applicable to the rights for the sublicensed country(ies), including allocation of costs for any activities conducted therein; 

 

	 	(c)	ChemoCentryx’s rights to use any data and results generated with respect to the sublicensed country(ies); 

  

	 	(d)	Rights to obtain licenses to Third Party intellectual property rights in the sublicensed country(ies); and 

  

	 	(e)	Consequences for the sublicensee’s breach of its sublicense agreement with Vifor. 

 4.
ChemoCentryx and Vifor intend that prior to June 30, 2018, Vifor will assign the rights granted in Section 2 above to VFMCRP. 
 5. No
activities will be conducted prior to June 30, 2018 under the license granted in Section 2 above with respect to the Vifor Territory except with the prior written approval of ChemoCentryx, which shall not be unreasonably withheld. Any
Development of the Product in the Vifor Territory will be conducted pursuant to the Development Plan. 
 6. In consideration for the rights
granted under this Letter, VIT shall make a non-refundable, non-creditable payment to ChemoCentryx of twenty million United States dollars (US$20,000,000), payable in the following two (2) installments:

  

	 	(a)	ten million United States dollars (US$10,000,000) within ten (10) Business Days after the date of this Letter; and 

  

	 	(b)	ten million United States dollars (US$10,000,000) on the first anniversary of the date of this Letter. 

  

					
		 	3.	  	Confidential

 7. If VFMCRP and ChemoCentryx enter into the amendment attached hereto as Exhibit A by June 30, 2018,
then this Letter will immediately terminate and be of no force and effect. 
 8. If VFMCRP and ChemoCentryx do not enter into the amendment attached
hereto as Exhibit A by June 30, 2018, then as promptly as possible following such date: 
  

	 	(a)	ChemoCentryx and VIT shall enter into a collaboration and license agreement that sets forth the terms and conditions for the Vifor Territory consistent with the VFMCRP Agreement but with necessary changes, as
discussed by ChemoCentryx and Vifor as of the date of this Letter; and 

  

	 	(b)	ChemoCentryx and VFMCRP shall amend the VFMCRP Agreement with necessary changes to take into account the agreement for the Vifor Territory referenced in Section 8(a), as discussed by ChemoCentryx and VIT as
of the date of this Letter. 

 9. This Letter may be executed in any number of counterparts, each of which shall be an original, but
all of which together shall constitute one instrument. This Letter may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original
signature had been delivered to the other party. 
 10. This Letter shall be governed by and construed in accordance with the laws of the
State of New York without reference to any rules of conflict of laws. 
 11. This Letter constitutes the entire agreement, both written and
oral, between ChemoCentryx and Vifor with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or implied, are superseded hereby, merged and canceled, and
are null and void and of no effect. 

  

					
		 	4.	  	Confidential

 If the foregoing is acceptable to you, please sign this Letter in the space provided below and
return it to me. 
  

			
	Sincerely,
	
	 CHEMOCENTRYX, INC.

		
	 By:
	 	/s/ Thomas J. Schall
	 Name:
	 	Thomas J. Schall
	 Title:
	 	President and Chief Executive Officer

 Agreed to and accepted as of the date of this Letter: 

 

			
	 VIFOR (INTERNATIONAL)
LTD.

		
	 By:
	 	/s/ Christoph Springer
	 Name:
	 	Christoph Springer
	 Title:
	 	Global Head of Business Development
		
	 By:
	 	/s/ Oliver P. Kronenberg
	 Name:
	 	Oliver P. Kronenberg
	 Title:
	 	Group General Counsel

  

					
		 	5.	  	Confidential

 Exhibit A 

AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT

 This AMENDMENT TO THE COLLABORATION AND
LICENSE AGREEMENT (the “Amendment”) is effective as of [            ], 2017 (the “Amendment Effective
Date”) by and between CHEMOCENTRYX, INC., a Delaware corporation, having an address at 850 Maude Avenue, Mountain View, CA 94043, U.S. (“ChemoCentryx”), and
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD., a corporation organized under the laws of Switzerland, having an address at Rechenstrasse
37, CH-9014 St. Gallen, Switzerland (“VFMCRP”). ChemoCentryx and VFMCRP may be referred to herein individually as a “Party” or collectively as the “Parties”. 

RECITALS 

A. ChemoCentryx and VFMCRP are parties to that certain Collaboration and License Agreement, dated May 9, 2016 (the
“Agreement”), pursuant to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX168 in certain countries. The Agreement was originally entered into between
Vifor (International) Ltd. (“VIT”) and ChemoCentryx and was subsequently assigned by VIT to VFMCRP. 
 B. On
February 8, 2017, ChemoCentryx and Vifor (International) Ltd. (“Vifor”) entered into a letter agreement pursuant to which ChemoCentryx granted Vifor an exclusive license to commercialize CCX168 in all countries of the world
(excluding the U.S. and China) that were not previously licensed to VFMCRP, and Vifor paid ChemoCentryx ten million United States dollars (US$10,000,000), equal to one-half of the total upfront payment for such rights. Such letter agreement is
terminated concurrently with the Parties’ entry into this Agreement. 
 C. This Amendment, which includes an option to expand
the territory licensed to VFMCRP to include China, and which is being entered into in accordance with Section 16.2 of the Agreement, provides for such territory expansion and payment therefor by VFMCRP in accordance with the terms and
conditions of this Amendment. 
 NOW, THEREFORE, the Parties agree as follows: 

 

	1.	AMENDMENT OF THE AGREEMENT 

The Parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective Date. Except to the
extent the Agreement is explicitly amended by this Amendment, the Agreement will remain in full force and effect in accordance with its terms. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings
such terms are given in the Agreement. 
 1.1 All references in the Agreement to “VIT” are hereby amended to refer instead
to “VFMCRP”. 
 1.2 Section 1.85 of the Agreement is hereby deleted and replaced in its entirety with the
following: 

  

 1.85 “Major Market Countries” means France, Switzerland, Germany, Italy,
Spain, the United Kingdom, Brazil, Japan, Canada, Mexico, South Korea and, if added to the VFMCRP Territory pursuant to Section 2.11, China.  

1.3 Section 1.134 of the Agreement is hereby deleted and replaced in its entirety with the following: 

1.134 “VFMCRP Territory” means (a) the world, excluding the U.S. and China, and (b) China, if China is added
to the VFMCRP Territory pursuant to Section 2.11. 
 1.4 The following new definitions are hereby added to the end of Article
1 of the Agreement as new Sections 1.136, 1.137 and 1.138: 
 1.136 “China” means the People’s Republic
of China, the Hong Kong Special Administrative Region of the People’s Republic of China and the Macao Special Administrative Region of the People’s Republic of China. 

1.137 “China Agreement” has the meaning set forth in Section 2.11. 

1.138 “China Agreement Revenue” means all amounts received by ChemoCentryx from a Third Party under a China Agreement,
but specifically excluding: (a) amounts received in consideration of the issuance of equity or debt securities of ChemoCentryx or its Affiliate; (b) payments for research, development, or commercialization activities undertaken by
ChemoCentryx or its Affiliate; (c) reimbursements for amounts paid or costs incurred by or on behalf of ChemoCentryx or its Affiliate, including patent prosecution, maintenance, enforcement or defense expenses; (d) amounts received as an
extension of credit or loan or as a distribution of a patent enforcement award; or (e) payments for the supply of goods and/or services. Notwithstanding the foregoing, if an upfront payment under a China Agreement includes amounts received in
consideration of the issuance of equity or debt securities of ChemoCentryx or its Affiliate, [***], will be included in China Agreement Revenue. [***]. In the event that ChemoCentryx grants rights to the Product along with a license to any
proprietary technology or intellectual property related to products other than the Product, ChemoCentryx shall reasonably and in good faith allocate the amounts received among all technology licensed or sublicensed, and China Agreement Revenue shall
include only the portion allocated to the Product. For clarity, China Agreement Revenue excludes amounts received by ChemoCentryx from a Third Party in connection with a sale of substantially all of the business or assets to which this Agreement
relates. 
 1.5 The last sentence of Section 2.10(d) of the Agreement and Section 2.10(e) of the Agreement are
hereby deleted. 
 1.6 The following new Section 2.11 is hereby added to the Agreement: 

2.11 China. ChemoCentryx shall notify VFMCRP within thirty (30) days after entering into a written agreement with a Third Party
for development of the  
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

 
Product for Regulatory Approval in China (a “China Agreement”). If ChemoCentryx has not entered into a China Agreement by [***], then VFMCRP may elect to expand the VFMCRP
Territory to include China by (a) delivering written notice of such expansion to ChemoCentryx and (b) paying ChemoCentryx a one-time, non-refundable, non-creditable payment of [***] United States dollars (US$[***]), in each case
(a) and (b) within thirty (30) days after [***]. Upon ChemoCentryx’s receipt of such notice and payment during such thirty (30)-day period, the VFMCRP Territory will automatically be expanded to include China. If ChemoCentryx
does not receive such notice and payment during such thirty (30)-day period, the VFMCRP Territory shall continue to exclude China. [Note: To be revised if these rights were granted to VIT prior to the execution of this Amendment.] 

1.7 The following new Section 8.5 is hereby added to the Agreement: 

8.5 China Agreement Revenue. Within sixty (60) days after the end of each Calendar Quarter in which ChemoCentryx receives China
Agreement Revenue, ChemoCentryx shall pay to VFMCRP an amount equal to [***] percent ([***]%) of all China Agreement Revenue received by ChemoCentryx during such Calendar Quarter. 

1.8 Section 9.4 of the Agreement is hereby deleted and replaced in its entirety with the following: 

9.4 Records; Audit. VFMCRP shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate records
pertaining to the sale or other disposition of the Product in sufficient detail to permit ChemoCentryx to confirm the accuracy of commercial milestone and royalty payments due hereunder. ChemoCentryx shall keep, and shall cause its Affiliates to
keep, complete and accurate records pertaining to the China Agreement Revenue received by ChemoCentryx in sufficient detail to permit VFMCRP to confirm the accuracy of payments due under Section 8.5. Such records shall be kept for such period
of time required by Applicable Laws, but in no case less than three (3) years following the end of the Calendar Quarter to which they pertain. Each Party shall have the right to have an independent, certified public accountant reasonably
acceptable to the other Party audit such records of the other Party to confirm Net Sales, royalties, and other payments, in the case of VFMCRP as audited Party, and to confirm China Agreement Revenue, in the case of ChemoCentryx as audited Party,
for a period covering not more than three (3) years following the Calendar Quarter to which they pertain. Such audits may be exercised only once for any period and no more than once per Calendar Year during normal business hours upon reasonable
prior written notice to the audited Party. Any such auditor shall not disclose the audited Party’s confidential information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports
furnished by the audited Party or the amount of payments by the audited Party under this Agreement. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days after the accountant’s report, plus 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 
interest (as set forth in Section 9.5) from the original due date. Any overpayment by the audited Party revealed by an audit shall be credited against future payments owed by the audited
Party to the other Party (and if no further payments are due, shall be refunded by the auditing Party at the request of the audited Party). The auditing Party shall bear the full cost of such audit unless such audit discloses an underpayment by the
audited Party of more than five percent (5%) of the amount of royalties or other payments due under this Agreement for any applicable Calendar Quarter, in which case, the audited Party shall bear the cost of such audit. 

 

	2.	PAYMENTS 

 2.1 In consideration for the expansion of the VFMCRP
Territory as set forth in this Amendment, VFMCRP shall make a non-refundable, non-creditable payment to ChemoCentryx of ten million United States dollars (US$10,000,000) on or before February 8, 2018;
provided that if the Agreement is terminated prior to such date, such payment shall remain due and payable despite such termination, unless the Agreement is terminated by VFMCRP pursuant to Section 14.3 of the Agreement. [Note: To be deleted
if this payment was made by VIT prior to the execution of this Amendment.] 
  

	3.	MISCELLANEOUS 

 3.1 Full Force and Effect. This Amendment amends
the terms of the Agreement and is deemed incorporated into the Agreement. The provisions of the Agreement, as amended by this Amendment, remain in full force and effect.  

3.2 Entire Agreement. The Agreement, as amended by this Amendment constitute the entire agreement, both written and oral, between the
Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or implied, are superseded hereby, merged and canceled, and are null and void and of no
effect. 
 3.3 Counterparts. This Amendment may be executed in one or more counterparts, each of which will be an original and all of
which together will constitute one instrument. 

  
 4 

 IN WITNESS WHEREOF, the
Parties have executed this Amendment as of the Amendment Effective Date. 
  

									
	CHEMOCENTRYX, INC.	 		 	VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.

									
					
	By:	 	 	 		 	By:	 	 
	Name:  	 	 	 		 	Name:  	 	 
	Title:	 	 	 		 	Title:	 	 
					
		 		 		 	By:	 	 
		 		 		 	Name:	 	 
		 		 		 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]